373 related articles for article (PubMed ID: 16186322)
1. Histopathological features and P-glycoprotein expression in retinoblastoma.
Filho JP; Correa ZM; Odashiro AN; Coutinho AB; Martins MC; Erwenne CM; Burnier MN
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3478-83. PubMed ID: 16186322
[TBL] [Abstract][Full Text] [Related]
2. Relationship between histopathological features of chemotherapy treated retinoblastoma and P-glycoprotein expression.
Souza Filho JP; Martins MC; Caissie AL; Torres VL; Fernandes LH; Erwenne CM; Burnier MN
Clin Exp Ophthalmol; 2005 Jun; 33(3):279-84. PubMed ID: 15932532
[TBL] [Abstract][Full Text] [Related]
3. The expression of cyclooxygenase 2 in retinoblastoma: primary enucleated eyes and enucleation after conservative treatment.
Souza Filho JP; Martins MC; Correa ZM; Odashiro AN; Antecka E; Coutinho AB; Macedo CR; Vianna RN; Burnier MN
Am J Ophthalmol; 2006 Oct; 142(4):625-31. PubMed ID: 17011855
[TBL] [Abstract][Full Text] [Related]
4. Nm23 expression in retinoblastoma.
Krishnakumar S; Lakshmi A; Shanmugam MP; Vanitha K; Biswas J
Ocul Immunol Inflamm; 2004 Jun; 12(2):127-35. PubMed ID: 15512982
[TBL] [Abstract][Full Text] [Related]
5. Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas.
Mu G; Liu H; Zhou F; Xu X; Jiang H; Wang Y; Qu Y
Hum Pathol; 2010 Apr; 41(4):493-502. PubMed ID: 20004941
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress in retinoblastoma: correlations with clinicopathologic features and tumor invasiveness.
Deepa PR; Nalini V; Mallikarjuna K; Vandhana S; Krishnakumar S
Curr Eye Res; 2009 Dec; 34(12):1011-8. PubMed ID: 19958119
[TBL] [Abstract][Full Text] [Related]
7. Expression of high mobility group A2 protein in retinoblastoma and its association with clinicopathologic features.
Venkatesan N; Kandalam M; Pasricha G; Sumantran V; Manfioletti G; Ono SJ; Reddy MA; Krishnakumar S
J Pediatr Hematol Oncol; 2009 Mar; 31(3):209-14. PubMed ID: 19262251
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological parameters and expression of P-glycoprotein and MRP-1 in retinoblastoma.
Kamburoğlu G; Kiratli H; Söylemezoğlu F; Bilgiç S
Ophthalmic Res; 2007; 39(4):191-7. PubMed ID: 17596751
[TBL] [Abstract][Full Text] [Related]
9. Retinoblastoma: expression of HLA-G.
Adithi M; Kandalam M; Ramkumar HL; Subramanian A; Venkatesan N; Krishnakumar S
Ocul Immunol Inflamm; 2006 Aug; 14(4):207-13. PubMed ID: 16911982
[TBL] [Abstract][Full Text] [Related]
10. Clinical pathologic study of a cohort of patients with retinoblastoma from a developing country.
Orellana ME; Fernandes BF; Arean C; Pifano I; Al-Kandari A; Burnier MN
J Pediatr Ophthalmol Strabismus; 2009; 46(5):294-9. PubMed ID: 19791727
[TBL] [Abstract][Full Text] [Related]
11. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic features of retinoblastoma and expression of VEGF and Ki-67 after comprehensive treatment].
Xue K; Qian J; Bi YW; Yao YQ; Yuan YF; DA CD
Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):134-41. PubMed ID: 21426843
[TBL] [Abstract][Full Text] [Related]
13. Expressions of Rac1, Tiam1 and Cdc42 in retinoblastoma.
Adithi M; Venkatesan N; Kandalam M; Biswas J; Krishnakumar S
Exp Eye Res; 2006 Dec; 83(6):1446-52. PubMed ID: 17027002
[TBL] [Abstract][Full Text] [Related]
14. The role of nitric oxide synthases and nitrotyrosine in retinoblastoma.
Adithi M; Nalini V; Krishnakumar S
Cancer; 2005 Apr; 103(8):1701-11. PubMed ID: 15754329
[TBL] [Abstract][Full Text] [Related]
15. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma.
Krishnakumar S; Sundaram A; Abhyankar D; Krishnamurthy V; Shanmugam MP; Gopal L; Sharma T; Biswas J
Cancer; 2004 Mar; 100(5):1059-69. PubMed ID: 14983503
[TBL] [Abstract][Full Text] [Related]
16. Differentiation in retinoblastoma and histopathological risk factors in Mexico.
Gómez-Martínez R; Rosales-Gradilla ME; Silva-Padilla N; Corona-Macías A
J Pediatr Ophthalmol Strabismus; 2013; 50(3):174-7. PubMed ID: 23477342
[TBL] [Abstract][Full Text] [Related]
17. Expression of C-kit in retinoblastoma: a potential therapeutic target.
Barry RJ; de Moura LR; Marshall JC; Fernandes BF; Orellana ME; Antecka E; Martins C; Burnier MN
Br J Ophthalmol; 2007 Nov; 91(11):1532-6. PubMed ID: 17591671
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma.
Chantada GL; Dunkel IJ; Antoneli CB; de Dávila MT; Arias V; Beaverson K; Fandiño AC; Chojniak M; Abramson DH
Pediatr Blood Cancer; 2007 Sep; 49(3):256-60. PubMed ID: 17029248
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas ligand in retinoblastoma.
Krishnakumar S; Kandalam M; Mohan A; Iyer A; Venkatesan N; Biswas J; Shanmugam MP
Cancer; 2004 Oct; 101(7):1672-6. PubMed ID: 15378505
[TBL] [Abstract][Full Text] [Related]
20. A histopathologic analysis of eyes primarily enucleated for advanced intraocular retinoblastoma from a developing country.
Kashyap S; Sethi S; Meel R; Pushker N; Sen S; Bajaj MS; Chandra M; Ghose S
Arch Pathol Lab Med; 2012 Feb; 136(2):190-3. PubMed ID: 22288967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
